Friday, July 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 3 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 12054487

    Muscarinic acetylcholine M1 receptor antagonists

    Contineum Therapeutics, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  2. US 11986511

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted May 21, 2024 · Expires May 16, 2044

    granted
  3. US 11975045

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted May 7, 2024 · Expires May 2, 2044

    granted
  4. WO 2024081718

    ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Apr 18, 2024 · Expires Apr 13, 2044

    granted
  5. US 11944666

    Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 2, 2024 · Expires Mar 28, 2044

    granted
  6. US 11926625

    HPK1 antagonists and uses thereof

    Nimbus Saturn, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  7. US 11912786

    Inhibitor of apoptosis protein (IAP) antagonists

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  8. US 11897873

    Kappa opioid receptor antagonists and products and methods related thereto

    BLACKTHORN THERAPEUTICS, INC. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  9. US 11890289

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Corcept Therapeutics Incorporated · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  10. US 11878074

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Jan 23, 2024 · Expires Jan 18, 2044

    granted
  11. US 11873291

    Quinoline cGAS antagonist compounds

    The Board of Regents of the University of Texas System · Granted Jan 16, 2024 · Expires Jan 11, 2044

    granted
  12. US 11866503

    Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  13. US 11858943

    Vasopressin receptor antagonists and products and methods related thereto

    Neumora Therapeutics, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  14. US 11844765

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  15. US 11845800

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  16. US 11840581

    α4β7 thioether peptide dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  17. US 11834409

    Heterocyclic NMDA antagonists

    Takeda Pharmaceutical Company Limited · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  18. US 11827601

    Heterocyclic NMDA antagonists

    Takeda Pharmaceutical Company Limited · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  19. US 11806398

    Citrate buffered VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  20. US 11771743

    Methods for preventing or treating allergy by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  21. US 11744800

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Sep 5, 2023 · Expires Aug 31, 2043

    granted
  22. US 11732024

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  23. US 11730705

    Small molecule CMKLR1 antagonists in inflammatory disease

    United States Government as represented by the Department of Veterans Affairs · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  24. US 11730794

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted